July 28, 2008 -- “Two years ago, when I decided to come back to China, I wanted an opportunity to change people’s lives and to help China’s pharmaceutical industry,” said Dr. Jin Li, COO of Shenogen Pharma Group, in an exclusive interview with ChinaBio® Today. “But if we do just what Western pharma does, we won’t develop a unique China pharmaceutical pathway,” he continued. Those words say a great deal about Dr. Li. But they also describe his company, Shenogen Pharma Group, which is a combination of Western practices and traditional Chinese medicines. It is also a highly innovative company that, despite its small size, is taking on a very large goal: small molecule and biologic drugs that are potential treatments for breast cancer and obesity. More details...
